1. < Home

Epidermal growth factor receptor

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

Goldman JW, Riess JW, Cho BC, Goldberg SB, Le X, Piotrowska Z, Okamoto I, Yu HA, García-Campelo R, de Castro Carpeño J, Ekman S, Reguart[...]

By afschroeder • October 24, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]

By afschroeder • June 27, 2026
Epidermal growth factor receptor signaling governs the host inflammatory response to invasive aspergillosis

Liu H, Lin J, Phan QT, Bruno VM, Filler SG. Epidermal growth factor receptor signaling governs the host inflammatory response to invasive aspergillosis. mBio. 2024[...]

By sjmartinez • October 31, 2024
EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy

Kang JJ, Ko A, Kil SH, Clair JM, Shin DS, Wang MB, Srivatsan ES. EGFR pathway targeting drugs in head and neck cancer in the[...]

By sjmartinez • October 30, 2022